Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis.
Maxim GrymonprezKevin VansprangheAndreas CapiauKoen BousseryStephane SteurbautLies LahoussePublished in: British journal of clinical pharmacology (2022)
Given the higher bleeding and mortality risks in NOAC-treated AF patients concomitantly using P-gp/CYP3A4 inhibitors, close monitoring is warranted.